Dranitsaris G[Author] - Search Results

Year	Number of Results
1987	1
1989	1
1994	1
1995	4
1996	1
1997	3
1998	5
1999	5
2000	2
2001	4
2002	2
2003	1
2004	7
2005	9
2006	11
2007	9
2008	4
2009	16
2010	10
2011	11
2012	12
2013	10
2014	15
2015	13
2016	8
2017	8
2018	4
2019	4
2020	3
2021	7
2022	7
2023	2

1

Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.

Pan A, Reingold RE, Zhao JL, Moy A, Kraehenbuehl L, Dranitsaris G, McBride SM, Scher HI, Kollmeier MA, Xiao H, Rathkopf DE, Lacouture ME. Pan A, et al. Among authors: dranitsaris g. J Urol. 2022 May;207(5):1010-1019. doi: 10.1097/JU.0000000000002425. Epub 2022 Jan 12. J Urol. 2022. PMID: 35020444 Clinical Trial.

2

Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis.

Nocco S, Andriano TM, Bose A, Chilov M, Godwin K, Dranitsaris G, Wu S, Lacouture ME, Roeker LE, Mato AR, Markova A. Nocco S, et al. Among authors: dranitsaris g. Crit Rev Oncol Hematol. 2022 Jun;174:103696. doi: 10.1016/j.critrevonc.2022.103696. Epub 2022 May 6. Crit Rev Oncol Hematol. 2022. PMID: 35523374 Review.

3

Clinical trial design in biosimilar drug development.

Dranitsaris G, Dorward K, Hatzimichael E, Amir E. Dranitsaris G, et al. Invest New Drugs. 2013 Apr;31(2):479-87. doi: 10.1007/s10637-012-9899-2. Epub 2012 Nov 17. Invest New Drugs. 2013. PMID: 23161336 Review.

4

Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs.

Dranitsaris G, Zhu X, Adunlin G, Vincent MD. Dranitsaris G, et al. Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):351-357. doi: 10.1080/14737167.2018.1467270. Epub 2018 Apr 25. Expert Rev Pharmacoecon Outcomes Res. 2018. PMID: 29681201 Review.

5

Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.

Dranitsaris G, Amir E, Dorward K. Dranitsaris G, et al. Drugs. 2011 Aug 20;71(12):1527-36. doi: 10.2165/11593730-000000000-00000. Drugs. 2011. PMID: 21861538 Review.

6

Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?

Sonpavde G, Dranitsaris G, Necchi A. Sonpavde G, et al. Among authors: dranitsaris g. Eur Urol. 2018 Jul;74(1):63-65. doi: 10.1016/j.eururo.2018.03.015. Epub 2018 Apr 10. Eur Urol. 2018. PMID: 29653886 No abstract available.

7

Pre-operative exercise and pyrexia as modifying factors in malignant hyperthermia (MH).

Riazi S, Bersselaar LRVD, Islander G, Heytens L, Snoeck MMJ, Bjorksten A, Gillies R, Dranitsaris G, Hellblom A, Treves S, Kunst G, Voermans NC, Jungbluth H. Riazi S, et al. Among authors: dranitsaris g. Neuromuscul Disord. 2022 Aug;32(8):628-634. doi: 10.1016/j.nmd.2022.06.003. Epub 2022 Jun 11. Neuromuscul Disord. 2022. PMID: 35738978 Free article.

8

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.

Lau C, Dranitsaris G. Lau C, et al. Among authors: dranitsaris g. Curr Oncol. 2022 Oct 26;29(11):8031-8042. doi: 10.3390/curroncol29110635. Curr Oncol. 2022. PMID: 36354695 Free PMC article. Review.

9

Drug tendering: drug supply and shortage implications for the uptake of biosimilars.

Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Dranitsaris G, et al. Clinicoecon Outcomes Res. 2017 Sep 29;9:573-584. doi: 10.2147/CEOR.S140063. eCollection 2017. Clinicoecon Outcomes Res. 2017. PMID: 29033595 Free PMC article. Review.

10

Advances in cancer therapeutics and patient access to new drugs.

Dranitsaris G, Truter I, Lubbe MS, Amir E, Evans W. Dranitsaris G, et al. Pharmacoeconomics. 2011 Mar;29(3):213-24. doi: 10.2165/11584210-000000000-00000. Pharmacoeconomics. 2011. PMID: 21184619 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results